International Journal of Pharmaceutical research and Applications
Volume 11, Issue 5, Sep.-Oct.2026, pp:878-891 www.ijprajournal.com ISSN:2456-4494

Real Time Release Testing (RTRT) In Pharmaceutical Industry: Analytical Technologies, Regulatory Landscapes and Future Perspective

Laxmi Narendra*, Dhara Patel, Grishma Patel, Dhananjay Meshram
Pioneer Pharmacy College, Nr. Ajwa Crossing, Sayajipura, Vadodara-390019, Gujarat, India.

Date of Submission: 07-10-2026 Date of Acceptance: 17-10-2026

Abstract:
Real-Time Release Testing (RTRT) is an advanced pharmaceutical quality-assurance approach that enables product quality to be evaluated using real-time process data, in-process measurements, and validated analytical technologies. Unlike conventional end-product testing, RTRT focuses on building quality into the manufacturing process through continuous monitoring and control. The integration of Process Analytical Technology (PAT), Quality by Design (QbD), multivariate data analysis, automation, and advanced analytical techniques facilitates improved understanding and control of critical material attributes and critical process parameters. This review discusses the principles, implementation strategies, pharmaceutical applications, advantages, challenges, and regulatory aspects of RTRT. The major benefits include reduced testing time, faster batch disposition, improved process understanding, reduced product waste, enhanced manufacturing efficiency, and consistent product quality. However, implementation can be challenging due to high initial investment, instrument calibration and validation requirements, data integrity and cyber security concerns, skilled workforce requirements, regulatory expectations, and integration with legacy manufacturing systems. Regulatory frameworks from organizations such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and International Council for Harmonisation (ICH) provide a scientific and risk-based foundation for implementing RTRT. Future developments involving Artificial Intelligence (AI), Machine Learning (ML), Digital Twins, Internet of Things (IoT), Big Data Analytics, and Industry 4.0 are expected to further enhance real-time quality monitoring and predictive manufacturing. RTRT therefore offers significant potential to modernize pharmaceutical manufacturing by enabling efficient, science-based, and continuous assurance of product quality.

Key words: Real-Time Release Testing, Process Analytical Technology, Quality by Design (QbD), US Food and Drug Administration (FDA), European Medicines Agency (EMA).

I. Introduction

Pharmaceutical Quality Assurance (QA) is a comprehensive and proactive framework of planned and systematic activities embedded within a quality system to ensure that pharmaceutical products meet the highest standards of safety, efficacy, and quality. QA builds safety into every step—from raw materials to final market release—following Good Manufacturing Practice (GMP)[1].

1.1 Core responsibility of QA

- Writing Procedures: Draft and update clear rules, called Standard Operating Procedures (SOPs), for all tasks.
- Validating Systems: Test machines and processes to prove they work correctly every single time.
- Controlling Documents: Keep strict records of batch files, logs, and test data.
- Managing Errors: Lead root-cause investigations when problems happen, fixing them with Corrective and Preventive Actions (CAPAs).
- Releasing Batches: Review all production data and give final approval before a drug goes to market.

1.2 Evolution from traditional Quality Control to RTRT

Traditional quality control methods rely heavily on manual inspection, physical sampling,and basic pen-and-paper tracking to catch defects after production occurs. The assurance of product quality in pharmaceutical manufacturing has traditionally relied on end-product testing, in which critical quality attributes (CQAs) are evaluated after production is completed. While this approach provides a final confirmation of product quality, it

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 5, Sep.-Oct.2026, pp:878-891 www.ijprajournal.com ISSN:2456-4494

offers limited insight into process variability and does not support timely intervention when deviations occur during manufacturing. These limitations are particularly evident in advanced manufacturing environments, such as continuous manufacturing, where process conditions evolve dynamically and require real-time monitoring and control. To address these challenges, real-time release testing (RTRT) has emerged as a strategy that enables product quality to be assessed based on in-process data within a framework of process understanding and risk-based control. With growing demand for faster production, strict compliance, and supply chain pressures, the industry needs an approach that is faster, more accurate, and more predictive. RTRT addresses each of these limitations by ensuring quality throughout the manufacturing process rather than merely checking it afterward [2].

1.3 Importance of RTRT in modern pharmaceutical manufacturing

RTRT is a modern quality assurance framework in pharmaceutical and biopharmaceutical manufacturing. It evaluates and ensures product quality using continuous process data and in-line sensors collected during production, rather than relying strictly on slow, post-production laboratory end-testing. It includes:

- Faster Batch Release: Shortens cycle times and accelerates time-to-market by removing bottlenecks in final laboratory testing.
- Proactive Quality Control: Builds quality directly into the product via Quality by Design (QbD) and Process Analytical Technology (PAT) rather than inspecting quality after the fact.
- Early Detection: Identifies out-of-specification issues immediately during the manufacturing phase to stop defective processing early.
- Lower Costs: Reduces the overall burden, material waste, and operational costs tied to repetitive physical lab testing.
- Higher Reliability: Delivers a deep, data-driven assurance that critical quality attributes are consistently met across every single unit.

1.4 Scope and Objective of RTRT:

This guideline outlines the requirements for applications that propose RTR testing for active substances, intermediates and finished products. It also outlines the different requirements that have to be fulfilled in the application and the need for interaction between quality assessors and GMP inspectors in the approval process. In the pharmaceutical and biopharmaceutical industries, RTRT is a regulatory-recognized quality assurance approach such as:

- Process Control & Analytics: Uses in-line, on-line, or at-line Process Analytical Technology (PAT) and sensors to monitor Critical Quality Attributes (CQAs) continuously during production.
- Application Range: Applicable to active pharmaceutical ingredients (APIs), intermediate products, and finished drug goods.
- Batch Release Mechanism: Replaces or supplements slow, destructive end-product lab testing with real-time data to justify immediate batch release.
- Lifecycle Framework: Operates on Quality by Design (QbD), validated mathematical models, and Continued Process Verification (CPV).
- The primary objective of Real-Time Release Testing (RTRT) is to evaluate and ensure product quality during manufacturing using continuous in-process data, replacing or reducing slow, traditional end-product laboratory testing. It includes:
- Build Quality In: Use Quality by Design (QbD) principles to monitor critical quality attributes (CQAs) proactively via sensors and Process Analytical Technology (PAT).
- Speed Up Approvals: Shorten manufacturing cycle and batch release times by avoiding post-production delays.
- Reduce Risk: Detect process drift or out-of-control conditions early to prevent the waste of full bad batches.
- Improve Reliability: Rely on continuous scientific process control rather than inspecting a small, random sample of the final product [3].

II. Concept of Real Time Release Testing (RTRT)

2.1 What is RTRT?

RTRT can be defined as “ability to evaluate and ensure the quality of In-process and or final product based on process data, which typically include a valid combination of measured material attributes and process controls”. In simpler terms, RTRT checks quality continuously while the product is

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 5, Sep.-Oct.2026, pp:878-891 www.ijprajournal.com ISSN:2456-4494

being made. This approach uses a combination of continuous monitoring, in-process controls, and advanced analytical technologies to ensure that each unit meets defined specifications without waiting for traditional QC checks at the end. RTRT does not replace QC; it transforms it into a predictive and proactive system. With strong scientific understanding, validated models, and automated controls, RTRT ensures that quality is built into the process instead of being tested afterward [2].



Fig 1: RTRT Process flowchart.

2.2 Principle of RTRT [5] :

Real-Time Release Testing (RTRT) is a quality assurance approach that evaluates and ensures product quality based on continuous process data collected during manufacturing rather than relying solely on traditional end-product laboratory testing.

RTRT is depend on 4 process, These are :

- **Quality by Design (QbD):** Builds quality directly into the product through deep scientific understanding and predefined objectives rather than inspecting it afterwards.
- **Process Analytical Technology (PAT):** Uses inline, online, or at-line measurement tools—such as Near-Infrared (NIR) or Raman spectroscopy—to monitor parameters where they occur.
- **Critical Quality Attributes (CQAs):** Focuses on tracking material attributes and Critical Process Parameters (CPPs) in real-time to guarantee that output specifications are met.
- **Validated State of Control:** Relies on robust, calibrated predictive models and multivariate data analysis to prove the system is stable and predictable.

Quality by design (QbD)[3]:

It is a systematic approach to product development that begins with predefined objectives and emphasizes product and process understanding and controls based on sound science and quality risk management (ICH Q8).The goals of pharmaceutical QbD may include the following:

- To achieve meaningful product quality specifications that are based on clinical performance.
- To increase process capability and reduce product variability and defects by enhancing product and process design, understanding, and control.
- To increase product development and manufacturing efficiencies.
- To enhance root cause analysis and post-approval change management.

The Key Concept of QbD is based on:

- Quality Target Product Profile (QTPP): A summary of the desired quality characteristics of a drug or product.
- Critical Quality Attributes (CQAs): Physical or chemical properties that must stay within specific limits to guarantee quality.
- Critical Process Parameters (CPPs): Operating limits and process variables that affect product quality and must be controlled.

Critical Quality Attributes [4-10]:

- A Critical Quality Attribute (CQA) is a physical, chemical, biological, or microbiological property or characteristic of a pharmaceutical product that must be controlled within defined limits to ensure

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 5, Sep.-Oct.2026, pp:878-891 www.ijprajournal.com ISSN:2456-4494

product quality, safety, and efficacy. CQAs are identified during the development phase and are essential components of Quality by Design (QbD) principles.

- Main Categories of CQAs...

- Physical Attributes: Particle size distribution, solid-state polymorphism, tablet hardness, and density.
- Chemical Properties: Assay/potency, pH levels, moisture/water content, degradation products, and chemical stability.
- Biological & Microbiological Attributes: Sterility, bioburden, endotoxin limits, and biological activity or potency assays.
- Impurity Profiles: Process-related impurities (like host cell proteins or residual solvents) and product-related variants (like aggregation or oxidation).

These attributes are critical because they directly impact the performance, stability, and therapeutic effectiveness of a drug product. Regulatory agencies such as the FDA and EMA require that CQAs be monitored and controlled throughout the product lifecycle. Examples of CQAs...

CQAs vary depending on the dosage form, route of administration, and therapeutic use.

- Purity and Impurity Levels: Presence of degradation products or residual solvents.
- Potency: The strength of the active pharmaceutical ingredient (API).
- Dissolution Rate: Especially important for oral solid dosage forms.
- Particle Size Distribution: Affects bioavailability and stability in inhaled or injectable products.
- pH and Osmolality: Critical for parenteral and ophthalmic products.

Critical Process Parameters (CPPs) [11]:

A Critical Process Parameter (CPP) is a manufacturing or operational variable that must be controlled within a specific range to ensure the final product meets its required quality, safety, and performance standards. In pharmaceutical manufacturing, ensuring consistent production of high-quality products is paramount. One of the key elements in achieving this goal is the rigorous control of Critical Process Parameters (CPPs). These parameters, including variables such as temperature, pH, pressure, and mixing speed, are crucial in determining the quality and efficacy of pharmaceutical products.

Importance of Critical Process Parameters...

- Control of CPPs is fundamental in pharmaceutical manufacturing for several reasons:
- Ensures Product Quality: By controlling CPPs, manufacturers can maintain the quality of the final product, ensuring it meets all regulatory and safety standards.
- Consistency and Reliability: Properly managed CPPs lead to consistent production processes, reducing variability and increasing reliability.
- Regulatory Compliance: Regulatory bodies require documentation and control of CPPs to ensure that pharmaceutical products are safe and effective.

Methodologies for Identifying CPPs...

Identifying CPPs involves a systematic approach that includes the following steps:

- Identifying CQAs: The first step is to identify the critical quality attributes of the product. These attributes are crucial for ensuring the product's efficacy, safety, and quality.
- Risk Assessment: Perform a risk assessment to determine which process parameters have a significant impact on CQAs. Tools such as Failure Mode and Effects Analysis (FMEA) and Ishikawa diagrams can be used.
- Design of Experiments (DoE): This statistical method helps in understanding the relationship between process parameters and CQAs by evaluating multiple parameters simultaneously.

Relationship between quality by design, critical process parameters and critical quality attributes [12, 13]:

Quality by Design (**QbD**) is the overall framework, Critical Quality Attributes (**CQAs**) define the required product traits, and Critical Process Parameters (**CPPs**) are the manufacturing controls adjusted to ensure those traits are met.

- QbD sets the destination**:** QbD starts with a goal—the Quality Target Product Profile (QTPP)—to decide what the patient needs.
- CQAs measure the product: QbD identifies which specific traits (CQAs) make the product safe and effective.
- CPPs control the process:_To get the right CQA results, engineers find out which machine settings (CPPs) change or affect those product traits. For example: Change a CPP (like raising the drying heat), and it alters a

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 5, Sep.-Oct.2026, pp:878-891 www.ijprajournal.com ISSN:2456-4494

CQA (like drug moisture or stability), which dictates whether the final product fits the QbD goal.



Fig 2: Relationship between (QbD),(CPPs) and (CQA)

PAT [Process Analytical Technology] in RTRT v[14],[22].

Process Analytical Technology (PAT) serves as the core technological backbone and data-generating engine for Real-Time Release Testing (RTRT). These innovative solution are revolutionizing drug production by offering efficiency, flexibility, and quality control. PAT, a framework introduced by the FDA, empowers real-time monitoring and control of pharmaceutical manufacturing. By integrating analytical techniques, sensors, and process control strategies, PAT ensures consistent product quality. This is achieved through continuous monitoring of critical process parameters (CPPs) and key performance indicators (KPIs), enabling manufacturers to promptly identify and rectify deviations, minimizing product variability.

Role of PAT in RTRT:

- Continuous Monitoring: PAT tools track Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) in real time (inline or online) rather than relying on delayed off-line laboratory testing.
- Data Provision: Technologies like Near-Infrared (NIR) and Raman spectroscopy measure attributes like chemical composition, moisture, and blend uniformity instantly and non-destructively.
- Quality Assurance: PAT supplies the validated multivariate data models and process understanding required by regulatory frameworks to justify releasing a batch based on how it was made.

Relationship between PAT and RTRT:

- PAT is the toolset: It uses inline sensors, spectroscopic instruments (like NIR or Raman), and multivariate analysis to measure Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) continuously during production.
- RTRT is the application/outcome: It uses the real-time data collected by PAT to evaluate product quality instantly, replacing or supplementing slow, traditional end-product lab testing for batch release.

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 5, Sep.-Oct.2026, pp:878-891 www.ijprajournal.com ISSN:2456-4494

- Dependence: RTRT cannot exist without PAT; RTRT relies entirely on the accuracy, speed, and validity of the continuous data provided by PAT systems. Together with Quality by Design (QbD), they shift quality control from retrospective inspection to active, real-time assurance.

III. Analytical technologies used in RTRT:

There are various techniques which rely on RTRT including....

- **Near-Infrared Spectroscopy (NIR):** Used in-line or at-line to monitor blend uniformity, moisture content, and tablet assay without destroying samples[13].
- **Raman Spectroscopy:** Preferred for applications involving aqueous solutions due to water's minimal interference, offering real-time compositional and structural data[14],[33].
- **Fourier-Transform Infrared Spectroscopy (FTIR):** Applied in bioprocessing and continuous manufacturing to track protein concentrations and impurities quickly.
- **Acoustic Resonance Spectrometry (ARS):** Measures physical attributes like tablet hardness and density directly on the production line.
- **UV-Vis Spectroscopy:** Measures protein concentration in bioprocessing and checks tablet surface porosity via light scattering.
- **UV/Vis and Refractive Index (RI) Detectors:** Deployed in-line during continuous downstream processing to measure real-time protein concentration and aggregation.
- **Mass Spectrometry (MS):** Provides online peptide mapping and identifies traImaging Technology: Employs hyperspectral cameras to map API distribution, coating thickness, and spot microbial growth early.ce chemical impurities or degradation immediately.
- **Imaging Technology:** Employs hyperspectral cameras to map API distribution, coating thickness, and spot microbial growth early.
- **Biosensors:** Monitors bioreactor metabolites (glucose/lactate) and checks for endotoxin contamination dynamically.
- **Chromatographic Techniques:** Uses automated at-line HPLC to track product purity and charge variants when optical sensors lack resolution.
- **Multivariate Data Analysis (MVA):** Uses chemometric models (such as Partial Least Squares) as statistical surrogates for complex off-line assays like drug dissolution.
- **Chemometrics:** Acts as the software brain, using mathematical models (like PLSR) to turn raw sensor data into quality metrics (e.g., predicting tablet dissolution).

IV. Implementation of RTRT in Pharmaceutical Manufacturing

Real-Time Release Testing (RTRT) is implemented by continuously monitoring Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) during manufacturing instead of relying only on finished-product testing.

Main steps:

- Identify CQAs and CPPs using Quality by Design (QbD).
- Establish a suitable control strategy.
- Use Process Analytical Technology (PAT) such as NIR or Raman spectroscopy for real-time monitoring.
- Develop and validate predictive/chemometric models for CQAs.
- Integrate PAT data with automated process control.
- Validate the system and obtain regulatory approval.
- Continuously monitor and verify the process throughout its lifecycle.

V. Application of RTRT [15-29]

Solid Oral Dosage Form

Real-Time Release Testing (RTRT) in solid oral dosage (OSD) forms is the ability to evaluate and ensure product quality continuously during manufacturing using inline, online, or at-line measurements instead of traditional offline end-product testing.

- Wet Granulation & Drying: Monitors moisture content and solid-state chemistry dynamically using NIR or microwave resonance sensors.
- Blending & Content Uniformity: Uses Near-Infrared (NIR) or Raman spectroscopy to non-destructively measure Active Pharmaceutical Ingredient (API) dispersion and content uniformity in real time.
- Compression & Tableting: Employs ultrasonic or reflection ray tracing

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 5, Sep.-Oct.2026, pp:878-891 www.ijprajournal.com ISSN:2456-4494

techniques to measure physical attributes, detect internal invisible cracks (capping/lamination), and monitor density.
- Coating: Integrates optical coherence tomography (OCT) to monitor film coating thickness and uniformity on tablets or pellets in real time.
- Dissolution Prediction: Combines physical parameters (particle size, porosity, coating thickness) via multivariate mathematical and partial least-squares (PLS) regression models to predict drug release profiles [29].

Sterile Pharmaceutical Products

Real-Time Release Testing (RTRT) in sterile pharmaceutical products replaces slow endproduct batch testing by evaluating quality in real time using process data, material attributes, and Process Analytical Technology (PAT).

- Parametric Release: Used mainly for terminally sterilized products (like vials and ampoules) to release batches based on verified sterilization cycle data instead of finished-product sterility tests.
- Aseptic Processing Control: Tracks critical environmental parameters, bioburden, and inline attributes, though full aseptic RTRT remains complex and heavily regulated.
- Continuous Verification: Reduces inventory holding times from weeks to days and cuts overall quality assurance costs.

Biopharmaceuticals[31]

Real-Time Release Testing (RTRT) in biopharmaceuticals evaluates and ensures product quality during manufacturing using continuous in-process data and sensor controls rather than relying solely on retrospective end-product testing.

- Cell Culture Monitoring: Tracks critical process parameters (CPPs) like pH, dissolved oxygen, and nutrient/metabolite levels (glucose or lactate) in real time.
- Raw Material Verification: Employs Raman spectroscopy or Near-Infrared (NIR) analysis to confirm the identity and variance of incoming media components.
- Purification and Chromatography Tracking: Monitors protein concentration, aggregate levels, and impurity clearance across column chromatography and filtration steps.
- Contamination Detection: Utilizes inline sensors to watch for early anomalies indicating potential microbial or viral shifts.

Vaccine Manufacturing

Real-Time Release Testing (RTRT) evaluates product quality during manufacturing using process and analytical data instead of relying only on slow post-production laboratory tests.

- Continuous Monitoring: Tracks critical process parameters (CPPs) like pH, temperature, dissolved oxygen, and metabolite levels live in bioreactors.
- Process Analytical Technology (PAT): Uses tools like Raman spectroscopy and NIR to measure cell density, viral titer, and protein conformation in real time.
- Data-Driven Models: Uses multivariate statistical models to confirm that critical quality attributes (CQAs) meet safety and potency standards during production.
- Automated Release: Permits fast batch approval when in-process data continuously proves the system remains in a validated state of control.

Personalized Medicine

RTRT uses Process Analytical Technology (PAT) to evaluate and approve medicine quality in real time based on continuous in-process data.

- 3D-Printed Pills: Instantly verifies the dosage and structure of custom, on-demand tablets printed for specific patients.
- Cell Therapies (CAR-T): Speeds up the release of a patient's own genetically modified cells, delivering life-saving treatments to critically ill patients in days instead of weeks.
- Precision Tumour Targeting: Dynamically adjusts the radiation beam to match the tumor's exact position, destroying cancer cells while sparing healthy tissue.

Cell and General Therapy Products

Real-time release testing (RTRT) in cell and gene therapy (CGT) allows manufacturers to evaluate product quality using continuous in-process data and Process Analytical Technology (PAT) rather than relying exclusively on sluggish end-point assays.

- Digital Twins and Predictive Analytics: Combines real-time biosensing with computational models to forecast critical quality attributes (CQAs) before processing finishes[39].

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 5, Sep.-Oct.2026, pp:878-891 www.ijprajournal.com ISSN:2456-4494

- Continuous Bioreactor Monitoring: Tracks parameters like pH, dissolved oxygen, viable cell density, and metabolite fluxes during T-cell or viral vector expansion.
- Feedback Control Systems: Uses online data streams to automatically adjust feeding rates or temperature within a validated design space, ensuring batch consistency.

VI. Advantages of RTRT :

- Improved product quality: Continuous monitoring of critical quality attributes (CQAs) and process parameters provides greater assurance of consistent product quality.
- Reduced testing and manufacturing costs: RTRT can reduce laboratory testing requirements, inventory time, rework, and batch rejection, improving manufacturing efficiency.
- Faster batch release: Enables quality assessment during manufacturing, reducing the time required for conventional end-product testing and batch release.
- Reduced variability: Continuous monitoring and feedback can improve intra-batch and batch-to-batch consistency.
- Supports continuous manufacturing: RTRT is particularly valuable for continuous manufacturing because quality can be assessed throughout the production process.
- Early detection of deviations: Process abnormalities and quality trends can be detected during manufacturing, allowing timely corrective action.
- Cost Reduction: RTRT can reduce manufacturing costs by decreasing the need for extensive conventional end-product testing, shortening batch-release time, and reducing laboratory workload. It can also minimize costs associated with reprocessing and rejected batches by allowing quality issues to be identified earlier in the process.
- Reduction of Product Waste: Real-time monitoring of critical quality attributes (CQAs) and critical process parameters (CPPs) helps detect process deviations at an early stage. This allows timely corrective actions and reduces the likelihood of producing large quantities of non-conforming products, thereby minimizing material and product waste.
- Regulatory Compliance: RTRT is supported within the regulatory framework of ICH Q8 (R2) and is associated with Quality by Design (QbD), Process Analytical Technology (PAT), and science- and risk-based control strategies. Properly validated RTRT systems can provide documented evidence that the manufacturing process consistently produces products meeting predefined quality requirements.
- Enhanced Process Understanding: RTRT promotes a deeper understanding of the relationship between material attributes, process parameters, and product quality. Continuous monitoring helps identify sources of variability and supports development of robust control strategies, thereby improving process consistency and product quality.

VII. Challenges and Limitations of RTRT :

- High Initial Investment: Implementation of RTRT requires significant initial investment in Process Analytical Technology (PAT) instruments, sensors, automation systems, software, data infrastructure, and validation activities. This may be a major barrier, particularly for small and medium-sized pharmaceutical manufacturers.
- Instrument Calibration and Validation: PAT instruments and analytical models used for RTRT require appropriate calibration, qualification, validation, and continuous performance monitoring. Changes in raw materials, instruments, or process conditions may require recalibration or model verification, increasing maintenance requirements.
- Data Integrity and Cybersecurity: RTRT generates large volumes of electronic process and analytical data. Ensuring data accuracy, traceability, security, and compliance with data-integrity principles such as ALCOA+ is essential. Automated systems also increase the need for appropriate cybersecurity controls.
- Skilled Workforce Requirement: Successful implementation requires personnel with multidisciplinary expertise

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 5, Sep.-Oct.2026, pp:878-891 www.ijprajournal.com ISSN:2456-4494

in pharmaceutical manufacturing, analytical techniques, PAT, statistics, chemometrics, automation, data management, validation, and regulatory requirements. Lack of appropriately trained personnel can hinder implementation.

- Regulatory Challenges: RTRT requires strong scientific and regulatory justification because quality decisions may depend on process data, analytical models, and automated systems rather than conventional end-product testing. Inadequate sampling strategies, model validation, documentation, or justification can create regulatory difficulties.
- Integration with Legacy Manufacturing Systems: Integrating modern PAT and RTRT technologies with existing manufacturing equipment, PLC/SCADA systems, MES, LIMS, and other legacy platforms can be technically complex. Differences in communication protocols, data formats, and system architectures may increase implementation time and cost.

VIII. Regulatory Landscape[1-8]

Overview of Global Regulatory Expectations: Real-Time Release Testing (RTRT) is an alternative to conventional end-product testing in which product quality is assured using process measurements, material attributes, process understanding, and an established control strategy. Regulatory authorities expect RTRT approaches to be scientifically justified, risk-based, validated, and supported by adequate process and product knowledge. The approach may replace all or selected finished-product tests when the demonstrated process control provides equivalent or greater assurance of product quality.

FDA Guidance on PAT and RTRT: The U.S. FDA's 2004 PAT Guidance provides the major regulatory foundation for PAT-based RTRT. It promotes a science- and risk-based approach to pharmaceutical development, manufacturing, and quality assurance. PAT implementation may involve real-time measurement, multivariate analysis, process monitoring and process control. FDA also supports flexible regulatory pathways for implementation of PAT systems through appropriate quality-system or regulatory-submission approaches.

EMA Guidelines: The EMA Guideline on Real-Time Release Testing (formerly Guideline on Parametric Release) specifically establishes requirements for applications proposing RTRT for active substances, intermediates, and finished products. EMA emphasizes that RTRT should be based on product knowledge, process understanding, critical process parameters (CPPs), critical material attributes (CMAs), and an appropriate control strategy. Partial RTRT, where RTRT is applied to selected CQAs while conventional testing remains for others, is also possible.

WHO Recommendations: WHO recommendations emphasize that analytical procedures used for pharmaceutical quality control must be suitable for their intended purpose and appropriately validated. WHO guidance specifically recognizes the use of PAT for RTRT and states that such technology should be validated to demonstrate that the product meets specifications throughout the production cycle and should be approved by the relevant regulatory authority.

ICH Guidelines:

ICH Guidelines	Relevance to RTRT
ICH Q8(R2)- Pharmaceutical Development	Provides the foundation for QbD, identification of CQAs, CPPs and development of a scientifically justified control strategy.
ICH Q9(R1)- Quality Risk Management	Supports risk-based identification and control of risks associated with RTRT systems, analytical methods, process parameters and data.
ICH Q10- Pharmaceutical Quality System	Provides the quality-system framework for implementation, monitoring, change management and continual improvement of RTRT throughout the product lifecycle
ICH Q13- Continuous Manufacturing	Supports RTRT within continuous manufacturing through integrated process monitoring, control strategies and PAT-based approaches
ICH Q14-Analytical Procedure Development	Specifically includes considerations for analytical procedures used for RTRT, including multivariate analytical procedures, robustness, control strategy and documentation.

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 5, Sep.-Oct.2026, pp:878-891 www.ijprajournal.com ISSN:2456-4494

Validation and Documentation Requirements: A successful RTRT system should be supported by documented evidence covering:

- Process and product understanding.
- Identification and justification of CQAs, CPPs and CMAs.
- Scientific justification of the RTRT strategy and acceptance criteria.
- Analytical procedure validation, including appropriate specificity, accuracy, precision, linearity/range and robustness.
- Calibration and qualification of PAT instruments.
- Validation/verification of chemometric or multivariate models where applicable.
- Sampling strategy and representativeness.
- Data integrity, electronic records and audit trails.
- Defined procedures for deviations, out-of-trend results and system failures.
- Change control and lifecycle management.
- Comparison/correlation between RTRT results and conventional reference testing.
- Validation reports, SOPs, risk assessments and regulatory submission documentation.

IX. Case studies [30-40]:

Case Study 1: Large-Scale Biopharmaceutical Company

A prominent biopharmaceutical company implemented RTRT to streamline the production of a complex biologic drug. By integrating in-line spectroscopy and advanced chemometrics, the company achieved real-time monitoring of critical quality attributes (CQAs). The RTRT system allowed for immediate adjustments during the manufacturing process, reducing the need for extensive end-product testing and minimizing batch release time.

Key Outcomes:

- Enhanced product consistency: The real-time data ensured that CQAs were consistently within specified ranges, leading to fewer deviations and enhanced product quality.
- Reduced time to market: By cutting down on the time required for end-product testing, the company accelerated its time to market, gaining a competitive edge. Cost savings: The reduction in testing and rework costs contributed to significant savings, underscoring the financial benefits of RTRT.

Case study 2: Generic Drug Manufacturer

A generic drug manufacturer adopted RTRT to address challenges associated with high-volume, low-margin production. The company implemented an RTRT system based on near-infrared (NIR) spectroscopy to monitor tablet compressibility and content uniformity in real-time.

Key Outcomes:

Improved efficiency: The RTRT system enabled real-time adjustments during tablet compression, reducing the incidence of out-of-specification (OOS) results.

Reduced waste: By minimizing the need for off-line testing and reprocessing, the company decreased production waste and improved overall efficiency.

Regulatory compliance: The successful implementation of RTRT helped the manufacturer meet regulatory expectations for quality control and contributed to smoother audits and inspections.

Case Study 3: Specialty Pharmaceutical Firm

A specialty pharmaceutical firm focused on RTRT to enhance the production of a high-value injectable drug. The company employed a combination of inline particle size analysis and automated feedback control systems to monitor and control the formulation process.

Key Outcomes:

Increased precision: The real-time monitoring of particle size distribution ensured that the injectable drug met stringent quality requirements, reducing variability and enhancing product safety.

Operational flexibility: The RTRT system allowed for quick adjustments to the formulation process, providing greater flexibility and responsiveness to production changes.

Enhanced customer confidence: The consistent quality and reliability of the product bolstered customer trust and reinforced the firm's reputation in the market.

Case studies 4: Success stories in RTRT implementation.

RTRT has already been employed by several large-scale pharmaceutical manufacturers such as Eli Lilly and AstraZeneca. AstraZeneca developed a system that blended PAT tools, in-process monitoring of stages like tablet hardness, and cGMP practices at various stages of commercial tablet manufacturing.

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 5, Sep.-Oct.2026, pp:878-891 www.ijprajournal.com ISSN:2456-4494

This was the first approach of its kind to obtain regulatory approval in 2007 in Europe. Eli Lilly contributed to the RTRT sphere through the development of a feed frame spectroscopic PAT tool allowing real-time measurement of active ingredient concentration within a final blend of a pharmaceutical powder. Having demonstrated its utility, Eli Lilly's RTRT feed frame approach was adopted in several markets as part of the conventional control strategy.

Case Studies 5: Successful Implementation of RTRT in Pharmaceutical Manufacturing.

Real-Time Release Testing (RTRT) represents a transformative approach in pharmaceutical manufacturing, allowing for immediate quality assurance and release of products based on real-time data. This paper presents a series of case studies highlighting successful implementations of RTRT across various pharmaceutical companies. Each case study explores the specific technologies and methodologies employed, the challenges encountered, and the benefits realized, such as reduced production cycles, enhanced product quality, and compliance with regulatory standards. By examining these real-world examples, the paper aims to provide valuable insights and practical guidance for companies seeking to adopt RTRT, demonstrating its potential to revolutionize quality control processes in the pharmaceutical industry.

X. Digital Transformation and Emerging Technologies :

a. Artificial Intelligence (AI): AI can analyze complex pharmaceutical manufacturing data and assist in process prediction, anomaly detection, quality monitoring, and decision-making. Its integration with PAT can support faster identification of process deviations and improve real-time quality assessment[35].

b. Machine Learning (ML): ML algorithms learn from historical and real-time manufacturing data and can be used to predict Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs). This can strengthen predictive process control and support RTRT-based quality decisions[39].

c. Digital Twins: Digital Twins are virtual representations of physical manufacturing processes or equipment that can be connected to real-time process data. They can support process simulation, optimization, predictive maintenance, and continuous manufacturing, thereby improving process understanding and manufacturing efficiency[39].

d. Internet of Things (IoT): IoT connects sensors, instruments, equipment, and manufacturing systems, allowing continuous collection and exchange of process data. This connectivity facilitates real-time monitoring, automated control, and rapid detection of process deviations, which are important for RTRT implementation.

e. Big Data Analytics: Pharmaceutical manufacturing produces large datasets from PAT instruments, manufacturing equipment, laboratory systems, and quality-control processes. Big Data Analytics enables identification of patterns, trends, correlations, and process variability, supporting process understanding and data-driven quality management.

f. Cloud Computing: Cloud Computing provides scalable infrastructure for data storage, processing, sharing, and advanced analytics. In pharmaceutical manufacturing, cloud-based systems can facilitate integration of manufacturing and quality data; however, implementation requires appropriate controls for data integrity, cybersecurity, access control, and regulatory compliance.

g. Industry 4.0 and Smart Manufacturing: Industry 4.0 integrates technologies such as AI, ML, IoT, robotics, Big Data, digital twins, and interconnected automation systems to create intelligent manufacturing environments. In pharmaceutical manufacturing, this approach can enable continuous process monitoring, predictive control, improved process understanding, and integration of RTRT into modern manufacturing systems[40].

XI. Future Prospects:

Real-Time Release Testing (RTRT) with regard to the level of support by the regulatory agencies and technological integration. The report also highlights challenges and opportunities in four areas :

- Regulatory Harmonization
- Expansion to new product categories
- Personal Medicine
- Integration with Industry 4.0 .

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 5, Sep.-Oct.2026, pp:878-891 www.ijprajournal.com ISSN:2456-4494

I. Regulatory Harmonization:
Greater harmonization among regulatory authorities such as FDA, EMA, and ICH may facilitate wider adoption of RTRT. ICH Q8, Q9 and Q10 provide the scientific and quality-system foundation for RTRT, while the EMA guideline specifically supports its application to active substances, intermediates, and finished products. Harmonized regulatory expectations could reduce differences between regions and simplify global implementation.

II. Expansion to new product categories:
RTRT has potential for broader application beyond conventional pharmaceutical products. Its principles can be applied to chemical and biological products, active substances, intermediates, and finished products, provided that adequate process understanding, control strategies, validated analytical methods, and appropriate regulatory justification are established.

III. Personalized Medicine:
The development of personalized and patient-specific medicines may create opportunities for RTRT because these products can require flexible and rapid manufacturing and quality assessment. Integration of PAT, advanced analytics, and real-time decision-making could support rapid confirmation of product quality for smaller or individualized production batches.

IV. Integration with Industry 4.0[40]:
RTRT is expected to become increasingly integrated with Industry 4.0 technologies, including IoT sensors, AI/ML, digital twins, Big Data analytics, and automated process control. Such integration can enable continuous data collection, predictive quality assessment, automated process adjustments, and faster batch-release decisions. A recent 2026 review identifies digitalization and advanced manufacturing technologies as important areas in the continuing development of RTRT.

XII. Conclusions:

Real-Time Release Testing represents an important advancement in pharmaceutical quality assurance by shifting the focus from traditional end-product testing toward continuous, science- and risk-based quality assurance. The integration of PAT, QbD, advanced analytical technologies, process monitoring, and multivariate data analysis provides greater process understanding and enables quality decisions to be supported by real-time manufacturing data. RTRT can reduce testing time, minimize product waste, improve manufacturing efficiency, and facilitate faster batch release while maintaining product quality. Despite these advantages, widespread implementation remains challenging because of high initial investment, analytical instrument calibration and validation, data integrity and cyber security requirements, availability of skilled personnel, regulatory expectations, and integration with existing manufacturing systems. Successful implementation therefore requires scientifically justified control strategies, validated analytical methods and models, robust data-management systems, and appropriate regulatory interaction. Current global regulatory guidance provides increasing support for RTRT within a well-understood and appropriately controlled manufacturing process. Future developments in artificial intelligence, machine learning, digital twins, Internet of Things, big-data analytics, cloud computing, and Industry 4.0 are expected to further strengthen RTRT capabilities. With continued technological advancement, regulatory harmonization, and development of reliable predictive models, RTRT has the potential to become an important component of modern pharmaceutical manufacturing and continuous quality assurance.

References:

[1]. U.S. Food and Drug Administration. PAT—A framework for innovative pharmaceutical development, manufacturing, and quality assurance: guidance for industry. Silver Spring (MD): FDA; 2004.
[2]. European Medicines Agency. Guideline on real-time release testing (formerly guideline on parametric release): revision 1. London: EMA; 2012. EMA/CHMP/QWP/811210/2009-Rev1.
[3]. International Council for Harmonisation. Pharmaceutical development Q8(R2). Geneva: ICH; 2009.
[4]. International Council for Harmonisation. Quality risk management Q9(R1). Geneva: ICH; 2023.
[5]. International Council for Harmonisation. Pharmaceutical quality system Q10. Geneva: ICH; 2008.

[6]. International Council for Harmonisation. Continuous manufacturing of drug substances and drug products Q13. Geneva: ICH; 2022.
[7]. International Council for Harmonisation. Analytical procedure development Q14. Geneva: ICH; 2023.
[8]. International Council for Harmonisation. Validation of analytical procedures Q2(R2). Geneva: ICH; 2023.
[9]. Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25(4):781-91. doi:10.1007/s11095-007-9511-1.
[10]. Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by design: concepts for ANDAs. AAPS J. 2008;10(2):268-76.
[11]. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Woodcock J, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771-83.
[12]. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27(1):26-34.
[13]. Roggo Y, Chalus P, Maurer L, Lema-Martinez C, Edmond A, Jent N. A review of near infrared spectroscopy and chemometrics in pharmaceutical technologies. J Pharm Biomed Anal. 2007;44(3):683-700. doi:10.1016/j.jpba.2007.03.023.
[14]. Esmonde-White KA, Cuellar M, Uerpmann C, Lenain B, Lewis IR. Raman spectroscopy as a process analytical technology for pharmaceutical manufacturing and bioprocessing. Anal Bioanal Chem. 2017;409(3):637-49. doi:10.1007/s00216-016-9824-1.
[15]. Markl D, Zeitler JA. A review of the use of process analytical technology for pharmaceutical manufacturing. Eur J Pharm Biopharm. 2017;112:1-16.
[16]. De Beer TRM, Burggraeve A, Fonteyne M, Saerens L, Remon JP, Vervaet C. Near infrared and Raman spectroscopy for the in-process monitoring of pharmaceutical production processes. Int J Pharm. 2011;417(1-2):32-47.
[17]. Blanco M, Alcalà M. Content uniformity and tablet hardness testing of intact pharmaceutical tablets by near infrared spectroscopy. Anal Chim Acta. 2006;581(2):318-26.
[18]. El-Hagrasy AS, Drennen JK 3rd. A process analytical technology approach to near-infrared process monitoring and control of pharmaceutical powder blending. J Pharm Sci. 2006;95(2):407-21
[19]. Lyon RC, Lester DS, Lewis EN, Lee E, Yu LX, Jefferson EH, et al. Near-infrared spectral imaging for quality assurance of pharmaceutical products: analysis of tablets to assess powder blend homogeneity. AAPS PharmSciTech. 2002;3(3):E17.
[20]. Sekulic SS, Ward HW, Brannegan DR, Stanley ED, Evans CL, Sciavolino ST, et al. On-line monitoring of powder blend homogeneity by near-infrared spectroscopy. Anal Chem. 1996;68(3):509-13.
[21]. Fonteyne M, Vercruysse J, Díaz DC, Govaert L, Vermeulen A, Remon JP, et al. Process analytical technology for continuous manufacturing of solid dosage forms.
[22]. Kim Y, Jeong SH, et al. Process analytical technology tools for monitoring pharmaceutical unit operations: a control strategy for continuous process verification. Pharmaceutics. 2021;13.
[23]. Lee SL, O'Connor TF, Yang X, Cruz CN, Chatterjee S, Madurawe RD, et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Innov. 2015;10:191-9.
[24]. Plumb K. Continuous processing in the pharmaceutical industry: changing the mind set. Chem Eng Res Des. 2005;83(6):730-8.
[25]. Mascia S, Heider PL, Zhang H, Lakerveld R, Benyahia B, Barton PI, et al. End-to-end continuous manufacturing of pharmaceuticals: integrated synthesis, purification, and final dosage formation. Angew Chem Int Ed Engl. 2013;52(47):12359-63.
[26]. Schaber SD, Gerogiorgis DI, Ramachandran R, Evans JMB, Barton PI, Trout BL. Economic analysis of integrated continuous and batch pharmaceutical manufacturing: a case study. Ind Eng Chem Res. 2011;50(17):10083-92.
[27]. Kleinebudde P, Khinast J, Rantanen J, editors. Continuous manufacturing of pharmaceuticals. Chichester: Wiley; 2017.
[28]. Pawar P, et al. First-principles and empirical approaches to predicting in vitro dissolution for pharmaceutical formulation and process development and for product release testing. Mol Pharm. 2019;16:3988-4000.
[29]. Chablani L, Taylor MK, Mehrotra A, Mansour HM, Kunnath K, Parcheri M, et al.

Prediction of drug dissolution from tablets using near-infrared spectroscopy and chemometrics. Int J Pharm. 2011;409(1-2):198-205.

[30]. Simon LL, Pataki H, Marosi G, Meemken F, Hungerbühler K, Baiker A, et al. Assessment of recent process analytical technology trends in pharmaceutical research and development. Org Process Res Dev. 2015;19(1):3-62.

[31]. Rolinger L, Rüdt M, Hubbuch J. A critical review of recent trends, and a future perspective of optical spectroscopy as PAT in biopharmaceutical downstream processing. Anal Bioanal Chem. 2020;412:2047-64. doi:10.1007/s00216-020-02407-z.

[32]. Graham L. Cross-industry applications for leveraging integrated process analytical technology (PAT) and data analytics applications. New Biotechnology. 2018 Oct;44:S40.

[33]. Esmonde-White KA, et al. The role of Raman spectroscopy in biopharmaceutical from development to manufacturing.

[34]. Wahlich J. Review: Continuous Manufacturing of Small Molecule Solid Oral Dosage Forms. Pharmaceutics. 2021 Aug 22;13(8):1311.

[35]. Casian T, Nagy B, Béla Kovács, Dorián László Galata, Hirsch E, Farkas A. Challenges and Opportunities of Implementing Data Fusion in Process Analytical Technology—A Review. Molecules. 2022 July 28;27(15):4846–6.

[36]. Park S, Park T, Han K. Real-Time Monitoring of Composite Wind Turbine Blades Using Fiber Bragg Grating Sensors. Advanced Composite Materials. 2011 Jan;20(1):39–51.

[37]. Cogdill RP, Anderson CA, Delgado-Lopez M, Molseed D, Chisholm R, Bolton R, et al. Process analytical technology case study part I: Feasibility studies for quantitative near-infrared method development. AAPS PharmSciTech. 2005 June;6(2):E262–72.https://link.springer.com/article/10.1208/pt060237

[38]. She C, Li M, Hou Y, Chen L, Wang J, Cao D. Near infrared spectroscopy as an alternative method for rapid determination of the solidification point of 2,4,6-trinitrotoluene in production. Journal of Near Infrared Spectroscopy. 2019 Apr 20;27(4):286–92.

[39]. Malheiro V, Duarte J, Veiga F, Filipa Mascarenhas-Melo. Exploiting Pharma 4.0 Technologies in the Non-Biological Complex Drugs Manufacturing: Innovations and Implications. Pharmaceutics [Internet]. 2023 Oct 28 [cited 2026 Sept 17];15(11):2545–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674941

[40]. Ravi Maharjan, Kim NA, Kim KH, Jeong SH. Transformative roles of digital twins from drug discovery to continuous manufacturing: pharmaceutical and biopharmaceutical perspectives. International Journal of Pharmaceutics X. 2025 Sept 1;100409–9.